Figure 3From: Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report Reticulocyte and red cell transfusions during rituximab therapy. Pattern of reticulocyte count and red cell transfusions over time since the diagnosis of pure red cell aplasia. Rituximab 375 mg/m2 was given weekly × 4 weeks during months 1 and 9 after diagnosis, as indicated by the vertical arrows at the top of the figure.Back to article page